Agilent - Breakthroughs in Immunotherapy- 2019 - 22

Breakthroughs in Immunotherapy

research and development paradigms for how to
intervene in disease. However, immune parameters
capable of sufficiently characterizing antitumor
responses across various immune networks are
underdeveloped. Converting the recent successes
of immunotherapy into broadly applicable clinical
research strategies with improved response rates
necessitates improving our ability to monitor
immunity at all stages of research, development,
diagnosis, and treatment.
Flow cytometry holds great potential to address this
gap as it is more compact, adaptable and accessible
than ever. Customizable and compatible with autosampling and high-throughput technology, increasingly
sensitive to a growing array of fluorophores, parallel
processing multiple inputs, cytometers allow us
to collect vast amounts of information from easily
obtained and processed samples. "We engineered
a new generation of cytometry to ensure that every
increment of enhanced performance was accessible
at the benchtop, with software that is easy to use.
The result is that investigators would be better able
to keep pace with the demand for the discovery and
implementation of novel immunotherapies", explained
Xiaobo Wang, (Figure 1). Dr Wang, former President
and Chief Technology Officer at ACEA Biosciences,
joined Agilent from ACEA, as General Manager of
the Flow Cytometry and Real-Time Cell Analysis
22

| GENengnews.com

Figure 1. NovoExpress has a user-friendly interface for easy access to settings, analysis, reports and
plates/sample layout.

http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019